BRAIN and NERVE－神経研究の進歩71巻11号

2019年11月発行

増大特集 ALS2019

HGFによる治療法開発

著者： 青木正志¹ 割田仁¹ 加藤昌昭¹ 鈴木直輝¹

所属機関： ¹東北大学大学院医学系研究科神経内科学

ページ範囲：P.1253 - P.1260

文献概要

われわれはALSに対する新規治療法の開発のために，ALSラットに対して肝細胞増殖因子（HGF）蛋白の髄腔内持続投与を行い，明確な治療効果を確認した。さらにマーモセットおよびカニクイザルに対するHGF蛋白の髄腔内持続投与による安全性（毒性）および薬物動態試験を行った。東北大学病院におけるALS患者に対する第Ⅰ相試験を経て，現在，大阪大学との2施設で医師主導治験による第Ⅱ相試験を行っている。

参考文献

1)Writing Group; Edaravone (MCI-186-19) ALS Study Group (Abe K, Aoki M, Tsuji S, et al.): Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16: 505-512, 2017

2)Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, et al: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62, 1993

3)Aoki M, Ogasawara M, Matsubara Y, Narisawa K, Nakamura S, et al: Mild ALS in Japan associated with novel SOD mutation. Nat Genet 5: 323-324, 1993

4)Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, et al: Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323: 1205-1208, 2009

5)Suzuki N, Aoki M, Warita H, Kato M, Mizuno H, et al: FALS with FUS mutation in Japan, with early onset, rapid progress and basophilic inclusion. J Hum Genet 55: 252-254, 2010

6)Taylor JP, Brown RH Jr, Cleveland DW: Decoding ALS: from genes to mechanism. Nature 539: 197-206, 2016

7)Akiyama T, Warita H, Kato M, Nishiyama A, Izumi R, et al: Genotype-phenotype relationships in familial amyotrophic lateral sclerosis with FUS/TLS mutations in Japan. Muscle Nerve 54: 398-404, 2016

8)Nishiyama A, Niihori T, Warita H, Izumi R, Akiyama T, et al: Comprehensive targeted next-generation sequencing in Japanese familial amyotrophic lateral sclerosis. Neurobiol Aging 53: 194, e1-e8, 2017［doi: 10.1016/j.neurobiolaging.2017.01.004］

9)Nakamura R, Sone J, Atsuta N, Tohnai G, Watanabe H, et al: Next-generation sequencing of 28 ALS-related genes in a Japanese ALS cohort. Neurobiol Aging 39: 219, e1-e8, 2016［doi: 10.1016/j.neurobiolaging.2015.11.030］

10)Nagai M, Aoki M, Miyoshi I, Kato M, Pasinelli P, et al: Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J Neurosci 21: 9246-9254, 2001

11)Egawa N, Kitaoka S, Tsukita K, Naitoh M, Takahashi K, et al: Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med 4: 145ra104, 2012［doi: 10.1126/scitranslmed.3004052］

12)Ichiyanagi N, Fujimori K, Yano M, Ishihara-Fujisaki C, Sone T, et al: Establishment of in vitro FUS-associated familial amyotrophic lateral sclerosis model using human induced pluripotent stem cells. Stem Cell Reports 6: 496-510, 2016

13)Fujimori K, Ishikawa M, Otomo A, Atsuta N, Nakamura R, et al: Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat Med 24: 1579-1589, 2018

14)Imamura K, Izumi Y, Watanabe A, Tsukita K, Woltjen K, et al: The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med 9: pii: eaaf3962, 2017［doi: 10.1126/scitranslmed.aaf3962］

15)Akiyama T, Suzuki N, Ishikawa M, Fujimori K, Sone T, et al: Aberrant axon branching via Fos-B dysregulation in FUS-ALS motor neurons. EBioMedicine 45: 362-378, 2019

16)Sun W, Funakoshi H, Nakamura T: Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS. J Neurosci 22: 6537-6548, 2002

17)Ishigaki A, Aoki M, Nagai M, Warita H, Kato S, et al: Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model. J Neuropathol Exp Neurol 66: 1037-1044, 2007

18)Kitamura K, Iwanami A, Nakamura M, Yamane J, Watanabe K, et al: Hepatocyte growth factor promotes endogenous repair and functional recovery after spinal cord injury. J Neurosci Res 85: 2332-2342, 2007

19)Kitamura K, Fujiyoshi K, Yamane J, Toyota F, Hikishima K, et al: Human hepatocyte growth factor promotes functional recovery in primates after spinal cord injury. PLOS ONE 6: e27706, 2011［doi: 10.1371/journal.pone.0027706］

20)Warita H, Kato M, Asada R, Yamashita A, Hayata D, et al: Safety, tolerability, and pharmacodynamics of intrathecal injection of recombinant human HGF (KP-100) in subjects with amyotrophic lateral sclerosis: a phase I trial. J Clin Pharmacol 59: 677-687, 2019

21)北村和也, 名越慈人, 辻　収彦, 渡辺航太, 福田健太郎, 他: HGFを用いた急性期脊髄損傷治療　治験開始までの道のりと今後の展望. 脊椎脊髄ジャーナル31: 545-551, 2018

22)Kitamura K, Nagoshi N, Tsuji O, Matsumoto M, Okano H, et al: Application of hepatocyte growth factor for acute spinal cord injury: the road from basic studies to human treatment. Int J Mol Sci 20: pii: E1054, 2019［doi: 10.3390/ijms20051054］

23)青木正志: 筋萎縮性側索硬化症（ALS）に対する治療開発への挑戦. 産学官連携ジャーナル, 2016年7月号　https://sangakukan.jst.go.jp/journal/journal_contents/2016/07/articles/1607-05/1607-05_article.html（最終閲覧日: 2019年8月1日）